Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System

Adv Ther. 2020 May;37(5):2344-2355. doi: 10.1007/s12325-020-01318-w. Epub 2020 Apr 15.

Abstract

Introduction: In Brazil, current data on the use of healthcare resources to manage individuals with overactive bladder (OAB) are lacking. This study aimed to characterize contemporary treatment and the economic burden among patients with OAB managed under the Brazilian public health system (Sistema Único de Saúde [SUS]).

Methods: Population-based data from January to December of 2015 were acquired from Brazil's public health database. Adults at least 18 years of age with an ICD-10 diagnostic code for OAB within the period were included. Records of outpatient visits, hospitalizations, and onabotulinumtoxinA injections were used to calculate estimates of resource use and costs (in Brazilian reals [R$]) among those with OAB (frequency [%] and mean (standard deviation [SD]) as appropriate). Patient identifiers were not available, so a record linkage methodology was used to match medical encounters to individuals. Pharmacologic management of OAB was informed by government medication purchases available from the official Brazilian government databases.

Results: During 2015, 26,640 patients with OAB were identified. All cohort members had at least one outpatient visit and 15,349 (57.6%) were hospitalized. Of the study cohort, 10.0% visited a general practitioner (GP), 41.3% visited a specialist, and 52.0% visited other non-medical healthcare practitioners within the year. Mean (SD) healthcare costs among the study cohort totaled R$355 (R$866) per patient per year; and were R$291 (R$654), R$27 (R$130), R$27 (R$30), and R$11 (R$17) for hospitalizations, GP, specialist, and non-medical healthcare practitioner visits per patient per year, respectively. Regional analysis of reported government medication purchases suggested that access to OAB treatments is highly limited.

Conclusions: High resource use and costs were estimated among patients with OAB managed within the SUS. These data provide a snapshot of the management of patients with OAB in Brazil, with the patients seeking treatment under SUS likely representing a more burdened subpopulation.

Keywords: Brazil public healthcare; Economic burden; Overactive bladder; Patient management; Urology.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use*
  • Brazil / epidemiology
  • Female
  • Health Care Costs
  • Hospitalization / statistics & numerical data*
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / therapeutic use
  • Patient Care Management* / methods
  • Patient Care Management* / statistics & numerical data
  • Public Health / statistics & numerical data
  • Retrospective Studies
  • Urinary Bladder, Overactive* / economics
  • Urinary Bladder, Overactive* / epidemiology
  • Urinary Bladder, Overactive* / therapy

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A